Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 3/2009

01-06-2009 | Research Article

Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain

Authors: Sebastián R. Martínez Pérez, Pedro D. Armando, Andrea C. Molina Guerra, Mercé Martí Pallarés, Fernando Martínez Martínez

Published in: International Journal of Clinical Pharmacy | Issue 3/2009

Login to get access

Abstract

Objectives The aim of this study is to determine the influence that different risk factors (age, gender, obesity, smoking, inactivity, diabetes mellitus and previous diagnosis of arterial hypertension) have on arterial pressure, and to determine the prevalence of patients that have high blood pressure and hypertension but have not received drug-treatment for arterial hypertension. Setting 42 Spanish community pharmacies. Method Observational and descriptive study. Patients included in the study were over 18 years of age, not receiving pharmacological treatment for arterial hypertension and not pregnant. Two measurements of arterial pressure were taken from each patient on the first day of the study and two other measurements on a later day. The average of these four measurements was taken as the arterial pressure value for the patient. All measurements were taken in the participating community pharmacies, always by the pharmacist and following the same protocols. The measurements were noted in the patients’ records along with data about the seven risk factors being studied, allowing them to be related with the patient’s arterial pressure value. Results The number of patients invited to join the study was 3,760, of whom 2,574 agreed to participate, with 2,094 completing the study. It was found that an increase in the number of risk factors led to a corresponding rise in the percentage of patients with high blood pressure and arterial hypertension. The risk of having arterial hypertension was 4.23 times higher in patients aged 65 years and over. It was also 2.88 times greater in those who had been previously diagnosed with arterial hypertension, 2.79 times higher in overweight or obese patients, 2.69 times more in diabetics and 2.22 times higher in men compared with in women. Prevalence of high blood pressure in patients not receiving pharmacological treatment for arterial hypertension was 33.6%, and prevalence of arterial hypertension was 22.8%. Conclusions Of the people studied, 22.8% had arterial hypertension. For the risk factors identified, those most related to the presence of arterial hypertension were, in descending order: being 65 years old or over, previous diagnosis of arterial hypertension, being overweight or obese, being diabetic and being male.
Literature
1.
go back to reference Moser M. Management of hypertension, part I. Am Fam Physician. 1996;53(7):2295–302.PubMed Moser M. Management of hypertension, part I. Am Fam Physician. 1996;53(7):2295–302.PubMed
2.
go back to reference Guidelines Committee. Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87. doi:10.1097/HJH.0b013e3281fc975a.CrossRef Guidelines Committee. Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87. doi:10.​1097/​HJH.​0b013e3281fc975a​.CrossRef
4.
go back to reference Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. doi:10.1001/jama.289.19.2560. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. doi:10.​1001/​jama.​289.​19.​2560.
5.
go back to reference Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Six Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 6 report. Arch Intern Med. 1997;157:2413–46. doi:10.1001/archinte.157.21.2413. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Six Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 6 report. Arch Intern Med. 1997;157:2413–46. doi:10.​1001/​archinte.​157.​21.​2413.
7.
go back to reference Williams B, et al. Guidelines for management of hypertension: report of the fourth working party of the British hypertension society, 2004––BHS IV. J Human Hypertens. 2004; 18(3): 139–85. Williams B, et al. Guidelines for management of hypertension: report of the fourth working party of the British hypertension society, 2004––BHS IV. J Human Hypertens. 2004; 18(3): 139–85.
8.
go back to reference Marín R, de la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc). 2005;125(1):36–46. doi:10.1157/13076404. Guidelines on the diagnosis and treatment of arterial hypertension in Spain 2005.CrossRef Marín R, de la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc). 2005;125(1):36–46. doi:10.​1157/​13076404. Guidelines on the diagnosis and treatment of arterial hypertension in Spain 2005.CrossRef
9.
go back to reference De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003; 24: 1601–10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003; 24: 1601–10.
10.
go back to reference Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004; 328: 634–40. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004; 328: 634–40.
11.
go back to reference Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003; 108: 2154–69. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003; 108: 2154–69.
13.
go back to reference Gired X, Mourad JJ, Vaïsse B, Poncelet P, Mallion JM, Herpin D. Estimation du nombre des sujets traités pour une HTA, una diabète ou une hyperlipidémie en France: étude FLASH 2002. Arch Mal Coeur. 2003;96:750–3. Estimation of the number of subjects treated for ATH, diabetes, or hyperlipidemia in France: FLAHS study 2002. Gired X, Mourad JJ, Vaïsse B, Poncelet P, Mallion JM, Herpin D. Estimation du nombre des sujets traités pour une HTA, una diabète ou une hyperlipidémie en France: étude FLASH 2002. Arch Mal Coeur. 2003;96:750–3. Estimation of the number of subjects treated for ATH, diabetes, or hyperlipidemia in France: FLAHS study 2002.
14.
go back to reference Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157–64.PubMedCrossRef Banegas JR, Rodríguez-Artalejo F, Ruilope LM, Graciani A, Luque M, de la Cruz-Troca JJ, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens. 2002;20:2157–64.PubMedCrossRef
16.
go back to reference Banegas JR, Rodríguez Artalejo F. El problema de la hipertensión arterial en España. Rev Clin Esp. 2002;202:12–5. The problem of hypertension in Spain. Banegas JR, Rodríguez Artalejo F. El problema de la hipertensión arterial en España. Rev Clin Esp. 2002;202:12–5. The problem of hypertension in Spain.
17.
go back to reference De la Figuera M, Arnau JM, Brotons C. Hipertensión arterial en Atención Primaria. [Arterial hypertension in primary care]. Badalona: Euromedice; 2002. ISBN 84-931353-0-5. De la Figuera M, Arnau JM, Brotons C. Hipertensión arterial en Atención Primaria. [Arterial hypertension in primary care]. Badalona: Euromedice; 2002. ISBN 84-931353-0-5.
19.
go back to reference Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D′Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure The Framingham heart study. Circulation. 2002;106:1–5.CrossRef Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D′Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure The Framingham heart study. Circulation. 2002;106:1–5.CrossRef
20.
go back to reference Mataix J, García torres L. Hipertensión arterial. [Arterial hypertension]. En: Mataix J. Nutrición y alimentación humana. [Nutricion and human alimentation]. Madrid: Ergon; 2002. ISBN 84-8473-088-3. Mataix J, García torres L. Hipertensión arterial. [Arterial hypertension]. En: Mataix J. Nutrición y alimentación humana. [Nutricion and human alimentation]. Madrid: Ergon; 2002. ISBN 84-8473-088-3.
21.
go back to reference Mayo Nápoles J, Pila Pérez R, Hernández Mandado P, Pila Peláez R, Guerra Rodríguez C. Hipertensión arterial en el joven: factores de riesgo. Rev Med Uruguay. 2000;16:24–30. Arterial hypertension in the young: risk factors. Mayo Nápoles J, Pila Pérez R, Hernández Mandado P, Pila Peláez R, Guerra Rodríguez C. Hipertensión arterial en el joven: factores de riesgo. Rev Med Uruguay. 2000;16:24–30. Arterial hypertension in the young: risk factors.
23.
go back to reference Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81. doi:10.1345/aph.1K311.PubMedCrossRef Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions part II: systematic review and meta-analysis in hypertension management. Ann Pharmacother. 2007;41(11):1770–81. doi:10.​1345/​aph.​1K311.PubMedCrossRef
25.
go back to reference Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother. 1993;27:555–8.PubMed Mason JD, Colley CA. Effectiveness of an ambulatory care clinical pharmacist: a controlled trial. Ann Pharmacother. 1993;27:555–8.PubMed
26.
go back to reference Lobas NH, Lepinski PW, Abramowitz PW. Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory-care clinic. Am J Hosp Pharm. 1992;49:1681–8.PubMed Lobas NH, Lepinski PW, Abramowitz PW. Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory-care clinic. Am J Hosp Pharm. 1992;49:1681–8.PubMed
27.
go back to reference Expert Panel on the Identification. Evaluation, and treatment of overweight and obesity in adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults; Executive summary. Am J Clin Nutr. 1998;68:899–917. Expert Panel on the Identification. Evaluation, and treatment of overweight and obesity in adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults; Executive summary. Am J Clin Nutr. 1998;68:899–917.
28.
go back to reference Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Sociedad Española para el Estudio de la Obesidad (SEEDO). Med Clin (Barc). 2000;115:587–97. Consensus SEEDO’2000 for the evaluation of overweight and obese people, and the establishment of therapeutic intervention. Spanish Society for the Study of Obesity (SEEDO). Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Sociedad Española para el Estudio de la Obesidad (SEEDO). Med Clin (Barc). 2000;115:587–97. Consensus SEEDO’2000 for the evaluation of overweight and obese people, and the establishment of therapeutic intervention. Spanish Society for the Study of Obesity (SEEDO).
31.
go back to reference Martínez Pérez SR, Sánchez Alonso FJ, Baena Parejo MI. Efectos de la intervención farmacéutica en pacientes con presión arterial elevada sin tratamiento farmacológico. Seguim Farmacoter. 2004;2(3):181–8. Effects of pharmaceutical intervention in patients with high blood pressure without pharmacological treatment. Martínez Pérez SR, Sánchez Alonso FJ, Baena Parejo MI. Efectos de la intervención farmacéutica en pacientes con presión arterial elevada sin tratamiento farmacológico. Seguim Farmacoter. 2004;2(3):181–8. Effects of pharmaceutical intervention in patients with high blood pressure without pharmacological treatment.
32.
go back to reference Carrión Valero L, Carballo Herencia JA, Divisón Garrote JA, Massó Orozco J, Artigao Rodenas LM, Sanchís Domenech C, et al. La oficina de farmacia puede mejorar el grado de conocimiento de la hipertensión arterial. Hipertension. 2002;19(7):299–304. Community pharmacies could improve awareness on arterial hypertension. Carrión Valero L, Carballo Herencia JA, Divisón Garrote JA, Massó Orozco J, Artigao Rodenas LM, Sanchís Domenech C, et al. La oficina de farmacia puede mejorar el grado de conocimiento de la hipertensión arterial. Hipertension. 2002;19(7):299–304. Community pharmacies could improve awareness on arterial hypertension.
33.
go back to reference Velázquez MO, Lara EA, Martínez MMY, Márquez FF. La detección integrada como un instrumento para vincular la prevención primaria, el tratamiento temprano y la vigilancia epidemiológica en diabetes e hipertensión arterial. Rev Endocrinol Nutr. 2000;8(4):129–35. Detection integrated as an instrument linked to primary care, early treatment and epidemiological vigilance in diabetes and arterial hypertension. Velázquez MO, Lara EA, Martínez MMY, Márquez FF. La detección integrada como un instrumento para vincular la prevención primaria, el tratamiento temprano y la vigilancia epidemiológica en diabetes e hipertensión arterial. Rev Endocrinol Nutr. 2000;8(4):129–35. Detection integrated as an instrument linked to primary care, early treatment and epidemiological vigilance in diabetes and arterial hypertension.
34.
go back to reference Martínez Pérez SR, Sánchez Alonso FJ. Determinación de factores de riesgo en pacientes con diferentes valores de presión arterial. Pharm Care Esp. 2006;8(5):200–8. Determination of risk factors en patients with different values of arterial pressure. Martínez Pérez SR, Sánchez Alonso FJ. Determinación de factores de riesgo en pacientes con diferentes valores de presión arterial. Pharm Care Esp. 2006;8(5):200–8. Determination of risk factors en patients with different values of arterial pressure.
40.
go back to reference Park JJ, Nelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting: drug therapy monitoring and counselling by pharmacists contributed to improved blood pressure control in study patients. J Am Pharm Assoc. 1996;36:443–51. Park JJ, Nelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting: drug therapy monitoring and counselling by pharmacists contributed to improved blood pressure control in study patients. J Am Pharm Assoc. 1996;36:443–51.
Metadata
Title
Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain
Authors
Sebastián R. Martínez Pérez
Pedro D. Armando
Andrea C. Molina Guerra
Mercé Martí Pallarés
Fernando Martínez Martínez
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 3/2009
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9267-7

Other articles of this Issue 3/2009

International Journal of Clinical Pharmacy 3/2009 Go to the issue